Yang, Z., Wang, X., Meng, R., Han, J., Li, Q., Cao, X. (2026). A molecular subtype–guided, chemotherapy-free neoadjuvant strategy using SHR-A1811 plus pertuzumab for hormone receptor–positive/HER2-positive breast cancer: A phase II trial in progress.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps653